Malaysian pharmaceutical firm Duopharma Biotech Berhad has signed a deal with the Russian investment fund behind Sputnik V to supply more than six million doses of the jab. RT speaks to the company’s chief operating officer, Wan Jeffery Majid, about whether to expect local production of the Russian vaccine in Malaysia, and why his company chose Sputnik V.
Malaysia to purchase 6.4 million Sputnik V vaccine doses
